[의학신문·일간보사=김영주 기자]’Hughel followed due process, and the complaint is unconfirmed.’
Recently, Huzel, the first domestic company to enter the Chinese market as a botulinum toxin, was engulfed in controversy over illegal toxin export. He emphasized that he did not comply with due process in the process of exporting to China, but Huzel emphasized that he was not working. He emphasized the end of exhausting debate in the industry, and did not hide doubts that the suspicion was initiated by re-rooting Huzel’s global expansion.
On the 3rd, E-Daily reported that Huzel was involved in the illegal distribution of botulinum toxin, and that a complaint was filed with the Food and Drug Administration.
E-Daily reported that Huzel passed over the botulinum toxin, which is subject to national shipment approval, to a wholesaler without separate approval to export to China, and that the wholesaler filed a complaint with the Food and Drug Administration stating this fact.
Botulinum toxin is subject to national shipment approval as a biological sanction. However, ▲If the importer requests it as a drug intended for export, ▲Except for items that the Minister of Food and Drug Safety determines to be exempt from national shipment approval, etc.
In his position, Huzel said, “We have been conducting business according to the legal procedure so far, and we will continue to strictly comply with the relevant laws.” He said, “The contents of the’indictment’ mentioned in the article have not been confirmed to date.” Revealed.
Huzel is the first Korean company to acquire an item license for the botulinum toxin formulation’Letybo’ in China last October, and is about to launch an official launch this week. I hope that the exhausting and unfounded suspicion and debate that exist in some parts of the industry will end.”